Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

BACKGROUND: The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, is currently being introduced throughout the African meningitis belt. In repeated multicentre cross-sectional studies in Burkina Faso we demonstrated a significant effect of vaccination on NmA carriage fo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Infect Dis
Главные авторы: Kristiansen, Paul A, Ba, Absatou Ky, Ouédraogo, Abdoul-Salam, Sanou, Idrissa, Ouédraogo, Rasmata, Sangaré, Lassana, Diomandé, Fabien, Kandolo, Denis, Saga, Inger Marie, Misegades, Lara, Clark, Thomas A, Préziosi, Marie-Pierre, Caugant, Dominique A
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2014
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4267149/
https://ncbi.nlm.nih.gov/pubmed/25472422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-014-0663-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы